Compounds > etoposide
Page last updated: 2024-08-23

etoposide and Dysmyelopoietic Syndromes

etoposide has been researched along with Dysmyelopoietic Syndromes in 90 studies

Research

Studies (90)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.11)18.7374
1990's39 (43.33)18.2507
2000's33 (36.67)29.6817
2010's17 (18.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T1
Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P1
Fujii, N; Fujiwara, D; Hamada, T; Iwatsuki, K; Kawakami, Y; Saeki, K; Sando, Y; Yamasaki, O1
Frouin, E; Hainaut, E; Puyade, M; Rioli, DI; Walter, A1
Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A1
Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Kobayashi, S; Kodaira, H; Matsukawa, Y; Miura, K; Takahashi, H; Takeuchi, J; Uchino, Y1
Behringer, K; Böll, B; Borchmann, P; Diehl, V; Eichenauer, DA; Engert, A; Franklin, J; Fuchs, M; Halbsguth, T; Haverkamp, H; Klimm, B; Rothe, A; Sasse, S; Thielen, I; von Tresckow, B1
Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L1
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY1
Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML1
Cheung, NK; Jhanwar, SC; Kramer, K; Kushner, BH; Modak, S; Qin, LX; Yataghena, K1
Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S1
Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N1
Bourke, B; Cortelazzo, S; Piccin, A; Rovigatti, U; Smith, OP1
Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M1
Andresen, S; Avalos, B; Bolwell, BJ; Copelan, E; Dean, R; Devine, S; Elder, P; Kalaycio, M; Mahindra, A; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Tench, S1
Ganser, A; Göhring, G; Hofmann, W; Lehmann, U; Luna, JC; Manukjan, G; Otto, N; Scherer, R; Schlegelberger, B; Steinemann, D; Welte, K1
Al-Ahmari, A; Al-Jefri, A; Al-Nounou, R; Al-Seraihy, A; Ayas, M; Belgaumi, A; El-Solh, H1
Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C1
Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S1
Badros, A; Barlogie, B; Morris, C; Tricot, G; Zangari, M1
Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ1
Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG1
Behm, FG; Blanco, JG; Boyett, JM; Evans, WE; Kun, LE; Pui, CH; Raimondi, S; Relling, MV; Rivera, GK; Sandlund, JT1
Kadowaki, S; Kawakami, K; Watanabe, Y1
Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R1
Christodoulou, J; Haferlach, T; Schnittger, S; Schoch, C1
Advani, R; Bennett, JM; Chin, DL; Dewald, G; Dugan, K; Greenberg, PL; Lee, SJ; Letendre, L; Lum, B; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS1
Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C1
Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M1
Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G1
Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J1
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M1
Kawauchi, K; Ogasawara, T; Yasuyama, M1
Fujinami, K; Maruta, I; Miura, T; Osada, Y; Takizawa, A; Tanaka, M1
Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N1
Cheung, NK; Choi, JK; Felix, CA; Jhanwar, SC; Kolaris, CP; Osheroff, N; Robinson, BW1
Arkenau, T; Cunningham, D; Horwich, A; Murphy, F; Norman, A; Oates, J; Powles, R; Sirohi, B; Wotherspoon, A1
Chan, T; Cooper, I; Januszewicz, E; Juneja, S; Wolf, M1
Ariyama, Y; Fujii, H; Nakagawa, H; Sonoda, Y1
Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Heimpel, H; Heit, W; Huber, C; Kolbe, K; Maschmeyer, G; Mitrou, PS1
Felix, CA; Hosler, MR; Lange, BJ; Masterson, M; Wilson, AE; Winick, NJ1
Molina, A; Nademanee, A; O'Donnell, MR; Parker, PM; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Stein, AS; Stepan, DE1
Nomura, T; Ogata, K1
Berdel, WE; Ho, AD; Knauf, WU; Kreuser, ED; Thiel, E1
Donaldson, SS; Ensign, LG; Heyn, R; Khan, F; Maurer, HM; Ruymann, F; Smith, MA; Vietti, T1
Andersson, M; Daugaard, G; Ersbøll, J; Hansen, SW; Hou-Jensen, K; Larsen, SO; Nielsen, D; Pedersen-Bjergaard, J; Philip, P; Sigsgaard, TC1
Cazenave, L; Gehan, E; Heyn, R; Khan, FM; Maurer, HM; Rubinstein, L; Smith, MA; Ungerleider, RS1
Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM1
Ishida, Y; Ito, T; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Shimosegawa, K; Utsugisawa, T1
Clausen, N; Hasle, H; Jacobsen, BB; Jacobsen, N; Kerndrup, G; Ostergaard, E; Yssing, M1
Andoh, K; Fujimoto, H; Funasako, M; Hata, N; Itoh, K; Itoh, Y; Nakai, S; Nishi, T; Ohata, M; Ono, H; Sato, H; Sato, Y; Taniji, M; Ueda, A1
Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P1
Dan, K; Ogata, K; Yamada, T1
Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K1
Bayle, C; Corti, C; Cosset, JM; Girinsky, T; Hayat, M; Nasr, F; Ribrag, V; Rougier, P; Theodore, C1
Crump, M; Dubé, I; Girouard, C; Imrie, KR; Keating, A; Prince, HM1
Doll, DC; Kasper, LM; List, AF; Taetle, R1
Dissing, M; Le Beau, MM; Pedersen-Bjergaard, J1
Adachi, M; Horiike, S; Huang, CL; Ieki, Y; Konaka, Y; Miyake, M; Onishi, R; Taki, T; Yagita, M1
Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G1
Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N1
Beyer, J; Biron, P; Bokemeyer, C; Droz, JP; Fléchon, A; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Schmoll, HJ; Schöffski, P1
Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M1
Hara, T; Moriwaki, H; Oyama, M; Sawada, M; Tsurumi, H; Yamada, T1
Ali, A; Alvi, S; Cartlidge, JD; Gregory, SA; Mativi, BY; Mundle, SD; Raza, A; Reza, S; Shetty, VT; Showel, MM; Venugopal, P1
Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J1
Anderson, JR; Arthur, D; Catalano, PJ; Freidlin, B; Heyn, R; Khayat, A; Krailo, M; Land, VJ; Miser, J; Rubinstein, L; Shuster, J; Smith, MA; Vena, D1
Fadeel, B; Hassan, Z; Hellström-Lindberg, E; Zhivotovsky, B1
Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D1
Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G1
Arber, DA; Bhatia, R; Bhatia, S; Forman, SJ; Fung, H; Kashyap, A; Krishnan, A; Molina, A; Nademanee, A; Niland, JC; O'Donnell, MR; Parker, PA; Slovak, ML; Sniecinski, I; Snyder, DS; Spielberger, R; Stein, A1
Fukuno, K; Goto, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yamada, T1
Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A1
Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T1
Arai, Y; Iwata, M; Kawano, A; Nakao, K; Nishino, M; Ohki, M; Takeuchi, K1
Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H1
Bieri, S; Chapuis, B; Helg, C; Miralbell, R1
Hishita, T; Kawanishi, S; Miura, Y; Nishihara, T; Tada-Oikawa, S; Tohyama, K; Tohyama, Y; Uchiyama, T; Yoshida, Y1
Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M1
Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C1
Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H1
Alberto, P; Mermillod, B; Zulian, GB1
Dan, K; Gomi, S; Ito, T; Nomura, T; Ogata, K; Ohki, I; Tanabe, Y; Yamada, T1
Daugaard, G; Hansen, SW; Larsen, SO; Pedersen-Bjergaard, J; Philip, P; Rørth, M1
Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C1
Ho, AD; Hunstein, W; Knauf, WU; Körbling, M1
Farhi, DC; Rosenthal, NS1
Anasetti, C; Appelbaum, FR; Beatty, P; Doney, K; Martin, P; Pepe, M; Stewart, P; Storb, R; Sullivan, KM; Witherspoon, R1
Clemens, MR; Ehninger, G; Gey, KF; Ladner, C1

Reviews

4 review(s) available for etoposide and Dysmyelopoietic Syndromes

ArticleYear
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
    American journal of hematology, 2017, Volume: 92, Issue:9

    Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult

2017
Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    American journal of hematology, 2005, Volume: 79, Issue:2

    Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cytarabine; Cytogenetic Analysis; Etoposide; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes

2005
Application of low-dose etoposide therapy for myelodysplastic syndromes.
    Leukemia & lymphoma, 1993, Volume: 12, Issue:1-2

    Topics: Acute Disease; Adult; Aged; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate

1993
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
    Leukemia, 2001, Volume: 15, Issue:6

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin

2001

Trials

22 trial(s) available for etoposide and Dysmyelopoietic Syndromes

ArticleYear
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
    Pediatric blood & cancer, 2017, Volume: 64, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult

2017
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine

2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
    International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
    International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism

2009
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
    Leukemia, 2009, Volume: 23, Issue:8

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult

2009
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.
    Blood, 2003, May-15, Volume: 101, Issue:10

    Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infant; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Placebos; Precursor Cell Lymphoblastic Leukemia-Lymphoma

2003
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Disease-Free Survival; Etoposide; Female; Genes, MDR; Humans; Logistic Models; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Survival Analysis; United States

2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Annals of hematology, 2004, Volume: 83, Issue:8

    Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome

2004
[Peripheral blood stem cell collection with high dose etoposide].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1995, Volume: 36, Issue:3

    Topics: Adult; Aged; Blood Component Removal; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma

1995
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
    Annals of hematology, 1993, Volume: 66, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction

1993
Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.
    Medical and pediatric oncology, 1994, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Extremities; Family Health; Female; Humans; Infant; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Meningeal Neoplasms; Myelodysplastic Syndromes; Neoplasms, Second Primary; Odds Ratio; Osteosarcoma; Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Risk Factors; Spinal Neoplasms

1994
Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
    Leukemia, 1996, Volume: 10, Issue:8

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Myelodysplastic Syndromes; Platelet Count; Remission Induction; Thioguanine; Treatment Outcome

1996
[Low-dose chemotherapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:9

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction

1996
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica
    Blood, 1997, Apr-01, Volume: 89, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome

1997
Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes.
    Leukemia research, 1998, Volume: 22, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome

1998
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
    British journal of haematology, 1998, Volume: 102, Issue:3

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome

1998
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leukemia; Male; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prospective Studies; Risk Factors; Vincristine

1998
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction

1995
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
    Annals of hematology, 2000, Volume: 79, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate

2000
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
    Leukemia, 2000, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome

2000
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
    Blood, 2001, Oct-15, Volume: 98, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous

2001
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Blood, 1990, Sep-01, Volume: 76, Issue:5

    Topics: Acute Disease; Anemia, Aplastic; Bone Marrow Transplantation; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Leukemia; Male; Methotrexate; Myelodysplastic Syndromes; Prednisone; Random Allocation; Risk Factors; Whole-Body Irradiation

1990

Other Studies

64 other study(ies) available for etoposide and Dysmyelopoietic Syndromes

ArticleYear
Successful use of etoposide for pyoderma gangrenosum associated with myelodysplastic syndrome and trisomy 8: cytokine profiles during treatment.
    European journal of dermatology : EJD, 2017, 10-01, Volume: 27, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; C-Reactive Protein; Chromosomes, Human, Pair 8; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-8; Middle Aged; Myelodysplastic Syndromes; Prothrombin Time; Pyoderma Gangrenosum; Trisomy

2017
Efficacy of etoposide for myelodysplasia cutis.
    European journal of dermatology : EJD, 2018, 04-01, Volume: 28, Issue:2

    Topics: Administration, Oral; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Immunohistochemistry; Male; Myelodysplastic Syndromes; Pruritus; Severity of Illness Index; Skin Neoplasms; Treatment Outcome

2018
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
    Annals of hematology, 2018, Volume: 97, Issue:11

    Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine

2018
Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.
    Chemotherapy, 2013, Volume: 59, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome

2013
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Blood, 2014, Mar-13, Volume: 123, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Germany; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Vincristine; Young Adult

2014
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.
    Pediatric blood & cancer, 2009, Volume: 53, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Neuroblastoma; Prospective Studies; Remission Induction; Risk Reduction Behavior; Topoisomerase II Inhibitors; Vincristine; Young Adult

2009
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
    Journal of the National Cancer Institute, 2010, Jun-16, Volume: 102, Issue:12

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine

2010
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; Combined Modality Therapy; Crohn Disease; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Male; Mercaptopurine; Mesalamine; Methyltransferases; Monosomy; Myelodysplastic Syndromes; Prednisone; Young Adult

2010
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Glyoxal; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednimustine; Prednisone; Procarbazine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Vinblastine; Vincristine

2011
Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.
    Bone marrow transplantation, 2012, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Young Adult

2012
ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia.
    Leukemia, 2011, Volume: 25, Issue:7

    Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Chromosome Aberrations; Disease Progression; DNA Methylation; Etoposide; Female; Humans; Interferon Regulatory Factors; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Proteins; Promoter Regions, Genetic

2011
Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome.
    Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:3

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2011
[Genetic prognostic factors in childhood acute myeloid leukemia].
    Klinische Padiatrie, 2012, Volume: 224, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic

2012
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
    Haematologica, 2013, Volume: 98, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome

2013
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:6

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Division; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Thalidomide; Vincristine

2002
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Journal of Korean medical science, 2002, Volume: 17, Issue:4

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous

2002
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Blood, 2003, May-01, Volume: 101, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome

2003
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 5; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Leukemia, Erythroblastic, Acute; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Mitoguazone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Vinblastine; Vincristine

2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2003
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
    Annals of hematology, 2004, Volume: 83, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Paclitaxel

2004
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction

2004
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Journal of experimental & clinical cancer research : CR, 2004, Volume: 23, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin

2004
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Follow-Up Studies; Germany; Germinoma; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Testicular Neoplasms; Translocation, Genetic; Transplantation, Autologous

2005
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
    Stem cells and development, 2005, Volume: 14, Issue:2

    Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine

2005
[A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2005, Volume: 96, Issue:7

    Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Testicular Neoplasms

2005
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lung Diseases; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tumor Burden

2006
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.
    Blood, 2008, Apr-01, Volume: 111, Issue:7

    Topics: Alkylating Agents; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Combined Modality Therapy; DNA Topoisomerases, Type II; Drosophila melanogaster; Etoposide; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Histone-Lysine N-Methyltransferase; Homeodomain Proteins; Humans; Male; Myelodysplastic Syndromes; Myeloid Ecotropic Viral Integration Site 1 Protein; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neuroblastoma; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Sequence Homology, Amino Acid; Topoisomerase II Inhibitors; Translocation, Genetic; Transplantation, Autologous

2008
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome

2008
Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases.
    Bone marrow transplantation, 1994, Volume: 13, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Myelodysplastic Syndromes; Prednisone; Procarbazine; Rectal Neoplasms; Risk Factors; Seminoma; Testicular Neoplasms; Transplantation, Autologous; Vincristine

1994
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Combined Modality Therapy; Dactinomycin; DNA-Binding Proteins; Etoposide; Female; Genes; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Radiotherapy; Teniposide; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Whole-Body Irradiation

1995
High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognos
    Blood, 1995, Mar-01, Volume: 85, Issue:5

    Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Whole-Body Irradiation

1995
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
    Leukemia & lymphoma, 1994, Volume: 12, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes

1994
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Leukemia, 1993, Volume: 7, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Cisplatin; Cohort Studies; Denmark; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Female; Germinoma; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Regression Analysis; Risk

1993
Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
    Journal of the National Cancer Institute, 1993, Apr-07, Volume: 85, Issue:7

    Topics: Acute Disease; Adult; Child; Clinical Trials as Topic; Etoposide; Humans; Incidence; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin

1993
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
    Leukemia & lymphoma, 1995, Volume: 19, Issue:5-6

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction

1995
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Cancer, 1996, Aug-01, Volume: 78, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Factors

1996
[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:10

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction

1996
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
    Clinical and laboratory haematology, 1996, Volume: 18, Issue:2

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 9; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Melphalan; Myelodysplastic Syndromes; Neoplastic Stem Cells; Occupational Diseases; Occupational Exposure; Pancytopenia; Remission Induction; Solvents; Translocation, Genetic; Transplantation, Homologous

1996
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
    Hematological oncology, 1996, Volume: 14, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Prednisone; Procarbazine; Prospective Studies; Radiotherapy, Adjuvant; Stomach Neoplasms; Vincristine

1996
New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis.
    Bone marrow transplantation, 1998, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Transplantation, Autologous; Whole-Body Irradiation

1998
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inversion; Chromosomes, Human, Pair 16; Etoposide; Female; Gene Rearrangement; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Topoisomerase I Inhibitors

1998
Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.
    International journal of oncology, 1998, Volume: 13, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Risk Factors

1998
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Mediastinal Neoplasms; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retroperitoneal Neoplasms; Retrospective Studies; Testicular Neoplasms

1998
[Cytarabine-induced pericarditis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:11

    Topics: Aged; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pericarditis

1998
Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes.
    American journal of hematology, 1999, Volume: 60, Issue:1

    Topics: Apoptosis; Bone Marrow Cells; DNA Fragmentation; DNA Nucleotidylexotransferase; DNA-Directed DNA Polymerase; Etoposide; HL-60 Cells; Humans; In Situ Nick-End Labeling; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Tumor Necrosis Factor-alpha

1999
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1999, Volume: 14, Issue:2

    Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins

1999
Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors

1999
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.
    Experimental hematology, 1999, Volume: 27, Issue:8

    Topics: Actins; Acute Disease; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Apoptosis; Blast Crisis; Caspase Inhibitors; Caspases; Cell Differentiation; Cysteine Proteinase Inhibitors; Cytoskeleton; Erythropoietin; Etoposide; fas Receptor; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tretinoin; Tumor Cells, Cultured

1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine

1999
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
    Blood, 2000, Mar-01, Volume: 95, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Radiation-Induced; Lymphoma; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Neoplasms, Second Primary; Odds Ratio; Radiotherapy; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation

2000
[An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes

2000
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
    Leukemia & lymphoma, 2000, Volume: 36, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction

2000
Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome.
    Internal medicine (Tokyo, Japan), 2000, Volume: 39, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Artificial Gene Fusion; Chromosome Inversion; Chromosomes, Human, Pair 11; Cytogenetics; Enzyme Inhibitors; Etoposide; Germinoma; Humans; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Nuclear Pore Complex Proteins; Nuclear Proteins; Nucleic Acid Synthesis Inhibitors; Retroperitoneal Neoplasms; RNA Helicases; Topoisomerase II Inhibitors; Translocation, Genetic

2000
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
    European journal of haematology, 2000, Volume: 65, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

2000
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
    International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2001
Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39.
    Cancer research, 2001, Apr-01, Volume: 61, Issue:7

    Topics: Anti-Bacterial Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cathepsin L; Cathepsins; Cell Line; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Cytochrome c Group; Endopeptidases; Enzyme Activation; Enzyme Inhibitors; Etoposide; Humans; Hydrogen-Ion Concentration; Intracellular Membranes; Leucine; Lysosomes; Macrolides; Membrane Potentials; Mitochondria; Myelodysplastic Syndromes; Proton-Translocating ATPases; Vacuolar Proton-Translocating ATPases

2001
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Leukemia & lymphoma, 2001, Volume: 40, Issue:5-6

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Transplantation, Autologous

2001
ABEP as primary chemotherapy for Hodgkin's disease.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

    Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine

1992
Low-dose etoposide: a potential therapy for myelodysplastic syndromes.
    British journal of haematology, 1992, Volume: 82, Issue:2

    Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes

1992
Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
    Lancet (London, England), 1991, Aug-10, Volume: 338, Issue:8763

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Cisplatin; Cohort Studies; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Risk Factors

1991
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
    Blood, 1991, Apr-01, Volume: 77, Issue:7

    Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation

1991
Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction

1990
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
    American journal of clinical pathology, 1991, Volume: 95, Issue:4

    Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors

1991
Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen.
    Cancer chemotherapy and pharmacology, 1989, Volume: 25, Issue:3

    Topics: Anemia, Aplastic; Antioxidants; beta Carotene; Bone Marrow Transplantation; Carotenoids; Combined Modality Therapy; Etoposide; Humans; Leukemia; Lipid Peroxidation; Lipid Peroxides; Myelodysplastic Syndromes; Parenteral Nutrition; Radiotherapy Dosage; Time Factors; Vitamin E

1989